Alternative titles; symbols
SNOMEDCT: 59990008; ICD10CM: E76.22; ORPHA: 581, 79270; DO: 0111394;
| Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
Gene/Locus |
Gene/Locus MIM number |
|---|---|---|---|---|---|---|
| 17q21.2 | Mucopolysaccharidosis type IIIB (Sanfilippo B) | 252920 | Autosomal recessive | 3 | NAGLU | 609701 |
A number sign (#) is used with this entry because Sanfilippo syndrome B, or mucopolysaccharidosis type IIIB, is caused by homozygous or compound heterozygous mutation in the gene encoding N-alpha-acetylglucosaminidase (NAGLU; 609701) on chromosome 17q21.
Sanfilippo syndrome B is an autosomal recessive lysosomal storage disorder characterized by the accumulation of heparan sulfate. Clinically, patients have progressive neurodegeneration, behavioral problems, mild skeletal changes, and shortened life span. The clinical severity ranges from mild to severe (Chinen et al., 2005).
For a phenotypic description and a discussion of genetic heterogeneity of Sanfilippo syndrome, or mucopolysaccharidosis III, see MPS IIIA (252900).
Harris (1961) may have reported the earliest case of Sanfilippo syndrome. The same patient was later shown by Neufeld (1973) to have MPS IIIB.
Van Schrojenstein-de Valk and van de Kamp (1987) reviewed 7 patients, aged 30 to 43 years, with a mild variant of Sanfilippo syndrome B. Somatic findings in these patients were unremarkable. Dementia and behavioral disturbances occurred late in the course of the disease. Four of the 7 patients were sibs in family A; 2 were sibs in family B, and the seventh was a double first cousin of these 2.
Yogalingam et al. (2000) reported a patient with an attenuated form of Sanfilippo syndrome B confirmed by genetic analysis (609701.0003; 609701.0010). The patient presented at 18 months of age with failure to thrive, developmental delay, hepatomegaly, and diarrhea. At age 3 he had coarse hair, a protuberant abdomen, soft hepatomegaly, and normal facies. Liver function testing and a skeletal survey were both normal. He was intellectually delayed with hyperactive aggressive behavior but showed no regression. He had had a slowly progressive course but was still alive at age 31. Functional studies showed significant residual NAGLU activity sufficient to metabolize 34% of intracellular 35-S-labeled GAG storage, suggesting that some mutant NAGLU was being correctly sorted to the lysosomal compartment. Yogalingam et al. (2000) suggested that the residual NAGLU activity could explain the attenuated phenotype in their patient.
The transmission pattern of MPS3B in the families reported by Tanaka et al. (2002) was consistent with autosomal recessive inheritance.
O'Brien (1972) determined that the defect in Sanfilippo syndrome B was absence or decreased activity of alpha-N-acetylglucosaminidase.
Andria et al. (1979) reported 3 sibs with MPS IIIB. Two sibs were severely affected and 1 was mildly affected. The finding of clinical heterogeneity within the same family was unusual. In cell fusion studies with cells from the mild case of Andria et al. (1979) and cells from severe cases, Ballabio et al. (1984) found no complementation, indicating that both mild and severe forms of the disorder are allelic.
Pande et al. (1992) described the daughter of first-cousin parents who had both MPS IIIB and Glanzmann disease (273800). Both disorders map to chromosome 17q21. In this family, there was no genetic linkage between the 2 disorders when studied by analyzing the heterozygotes. While the mother of the proband had NAGLU activity levels in the heterozygous range, the father had normal levels similar to those of a wildtype homozygote. Several family members had abnormally high levels of NAGLU activity, consistent with a 'hyperactive' allele, as had been demonstrated by Vance et al. (1980, 1981) and by Pericak-Vance et al. (1985). Pande et al. (1992) concluded that the father of the proband had an unusual NAGLU genotype: a combination of a hyperactive allele and a defective allele. The findings indicated that normal levels of the NAGLU enzyme can be found in obligate heterozygotes, thus precluding genotype classification on a biochemical basis alone.
Prenatal Diagnosis
Kleijer et al. (1984) made the prenatal diagnosis of Sanfilippo syndrome B and found that elevated heparan sulfate in the amniotic fluid complemented the enzyme assay.
Minelli et al. (1988) made the prenatal diagnosis of Sanfilippo syndrome B by chorionic villus sampling.
Vellodi et al. (1992) performed bone marrow transplantation in twin sisters with Sanfilippo syndrome B. The diagnosis was made at the age of 18 months, at which time they were clinically normal, on the basis of abnormal excretion of heparan sulfate in the urine and deficiency of glucosaminidase in the plasma and leukocytes; the diagnosis was suspected because an older brother was affected. The transplant was first done from the haploidentical father; there was no engraftment in either so that a second transplant was carried out with success from the haploidentical mother. Follow-up for 9 years posttransplant showed that neither twin was as handicapped as the untreated brother at the same age; other evidence of beneficial effect was recorded.
Muschol et al. (2023) reported results of an open-label phase I/II study of intracerebroventricular administration of tralesinidase alfa in 22 patients with Sanfilippo syndrome B. Administration of an optimized dose of intracerebroventricular for 48 weeks resulted in normalized heparan sulfate and heparan sulfate nonreducing end (HS-NRE) levels in the CSF and plasma and stabilized cortical gray matter volume. Additionally, hepatomegaly resolved in most patients. An inverse correlation was observed between cumulative plasma HS-NRE levels and change in cognitive age equivalent (AEq) scores. Muschol et al. (2023) hypothesized that the normalization of plasma heparan sulfate and HS-NRE through intracerebroventricular administration of tralesinidase alfa may have been due to glymphatic function, resulting in improved efficacy.
Wenger et al. (2000) described a child who had Sanfilippo syndrome B with a homozygous mutation in the NAGLU gene, glycogen storage disease (GSD) type Ia (232200), and a presumably balanced translocation between chromosomes 12 and 20. The parents were nonconsanguineous and of Czechoslovakian/Hungarian ancestry; 3 of the 4 grandparents were 'ethnically similar.' The karyotype of the father and a normal brother was 46,XY. The mother was 45,X in lymphoblasts and mosaic 45,X/47,XXX in fibroblasts. Both Sanfilippo syndrome B and GSD Ia map to chromosome 17q21, suggesting a common mechanism. Wenger et al. (2000) stated that it was highly unlikely that the 2 recessive disorders and the de novo translocation in the same patient were unrelated occurrences.
Using SSCP analysis of PCR-amplified segments of genomic DNA from patients with Sanfilippo syndrome B, Zhao et al. (1996) identified several recessive mutations in the NAGLU gene (see, e.g., 609701.0001-609701.0005).
In a mutation screen of 20 patients with Sanfilippo syndrome B, Tessitore et al. (2000) identified 28 mutations, 14 of which were novel, in the NAGLU gene. Of these mutations, 4 were found in homozygosity and only 1 was seen in 2 different patients, showing the remarkable molecular heterogeneity of the disorder.
Tanaka et al. (2002) performed molecular analysis of the NAGLU gene in 7 Japanese patients with Sanfilippo syndrome B from 6 unrelated families; 6 disease-causing mutations were found, of which 2 were novel. Two families were from Okinawa, where more patients with Sanfilippo syndrome were found than in other areas in Japan. Two sibs, who were compound heterozygous for F314L (609701.0011) and R565P (609701.0009), showed an attenuated form. Two patients with a severe phenotype with rapid progression were homozygous for R482W (609701.0012) and R565P, respectively. Tanaka et al. (2002) suggested that the R565P mutation is common in Okinawa. Chinen et al. (2005) identified the homozygous R565P mutation in 5 unrelated Japanese patients from Okinawa, suggesting a founder effect.
Najmabadi et al. (2011) performed homozygosity mapping followed by exon enrichment and next-generation sequencing in 136 consanguineous families (over 90% Iranian and less than 10% Turkish or Arab) segregating syndromic or nonsyndromic forms of autosomal recessive intellectual disability. They identified a family (8600486) in which 3 of 4 children, born to parents related as first cousins once removed, had MPS IIIB (severe intellectual disability, autism spectrum disorder, and coarse facial features) and a homozygous missense mutation in the NAGLU gene (609701.0014).
In series of cases of Sanfilippo syndrome collected in most parts of the world, type A is more frequent than type B. Among 11 patients in Greece, however, Beratis et al. (1986) found that 10 had type B and 1 had type A. Both parents of the latter patient came from the Greek ethnic community of Turkey. All of the type B cases came from east-central Greece and neighboring areas of Thessaly and Macedonia.
Using multiple ascertainment sources, Nelson et al. (2003) obtained an incidence rate for Sanfilippo syndrome (all forms combined) in western Australia for the period 1969 to 1996 of approximately 1 in 58,000 live births; there were a total of 11 cases, including 5 of type A, 5 of type B, and 1 of type C.
Mangas et al. (2008) noted the MPS IIIB is the most common form of MPS among Portuguese. The authors identified a founder mutation (R234C; 609701.0013) in the NAGLU gene, which accounted for 32% of mutant alleles in their study of 11 Portuguese patients with the disorder. Haplotype analysis showed that the R234C mutation arose on a founder haplotype common to both Spanish and Portuguese individuals, suggesting that the mutation had a single and relatively recent origin in the Iberian peninsula.
Ellinwood et al. (2003) reported naturally occurring Sanfilippo syndrome IIIB in Schipperke dogs. Two affected dogs presented at about 3 years of age with progressive ataxia, tremors, and lethargy. Other findings included mildly dystrophic corneas and small peripheral foci of retinal degeneration. Naglu activity was less than 10% of normal values. Postmortem examination showed severe cerebellar atrophy with marked Purkinje cell loss.
Andria, G., Di Natale, P., del Giudice, E., Strisciuglio, P., Murino, P. Sanfilippo B syndrome (MPS III B): mild and severe forms within the same sibship. Clin. Genet. 15: 500-504, 1979. [PubMed: 157237] [Full Text: https://doi.org/10.1111/j.1399-0004.1979.tb00832.x]
Ballabio, A., Pallini, R., Di Natale, P. Mucopolysaccharidosis IIIB: hybridization studies on fibroblasts from a mild case and fibroblasts from severe patients. Clin. Genet. 25: 191-195, 1984. [PubMed: 6231143] [Full Text: https://doi.org/10.1111/j.1399-0004.1984.tb00484.x]
Beratis, N. G., Sklower, S. L., Wilbur, L., Matalon, R. Sanfilippo disease in Greece. Clin. Genet. 29: 129-132, 1986. [PubMed: 3082543] [Full Text: https://doi.org/10.1111/j.1399-0004.1986.tb01235.x]
Chinen, Y., Tohma, T., Izumikawa, Y., Uehara, H., Ohta, T. Sanfilippo type B syndrome: five patients with an R565P homozygous mutation in the alpha-N-acetylglucosaminidase gene from the Okinawa islands in Japan. J. Hum. Genet. 50: 357-359, 2005. [PubMed: 15933803] [Full Text: https://doi.org/10.1007/s10038-005-0258-4]
Ellinwood, N. M., Wang, P., Skeen, T., Sharp, N. J. H., Cesta, M., Decker, S., Edwards, N. J., Bublot, I., Thompson, J. N., Bush, W., Hardam, E., Haskins, M. E., Giger, U. A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs. J. Inherit. Metab. Dis. 26: 489-504, 2003. [PubMed: 14518829] [Full Text: https://doi.org/10.1023/a:1025177411938]
Harris, R. C. Mucopolysaccharide disorder: a possible new genotype of Hurler's syndrome. (Abstract) Am. J. Dis. Child. 102: 741 only, 1961.
Kleijer, W. J., Huijmans, J. G. M., Blom, W., Gorska, D., Kubalska, J., Walasek, M., Zaremba, J. Prenatal diagnosis of Sanfilippo disease type B. Hum. Genet. 66: 287-288, 1984. [PubMed: 6427096] [Full Text: https://doi.org/10.1007/BF00287628]
Mangas, M., Nogueira, C., Prata, M. J., Lacerda, L., Coll, M. J., Soares, G., Ribeiro, G., Amaral, O., Ferreira, C., Alves, C., Coutinho, M. F., Alves, S. Molecular analysis of mucopolysaccharidosis type IIIB in Portugal: evidence of a single origin for a common mutation (R234C) in the Iberian Peninsula. Clin. Genet. 73: 251-256, 2008. [PubMed: 18218046] [Full Text: https://doi.org/10.1111/j.1399-0004.2007.00951.x]
Minelli, A., Danesino, C., Lo Curto, F., Tenti, P., Zampatti, C., Simoni, G., Rossella, F., Fois, A. First trimester prenatal diagnosis of Sanfilippo disease (MPSIII) type B. Prenatal Diag. 8: 47-52, 1988. [PubMed: 3125534] [Full Text: https://doi.org/10.1002/pd.1970080106]
Muschol, N., Koehn, A., von Cossel, K., Okur, I., Ezgu, F., Harmatz, P., de Castro Lopez, M. J., Couce, M. L., Lin, S. P., Batzios, S., Cleary, M., Solano, M., Nestrasil, I., Kaufman, B., Shaywitz, A. J., Maricich, S. M., Kuca, B., Kovalchin, J., Zanelli, E. A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B. J. Clin. Invest. 133: e165076, 2023. [PubMed: 36413418] [Full Text: https://doi.org/10.1172/JCI165076]
Najmabadi, H., Hu, H., Garshasbi, M., Zemojtel, T., Abedini, S. S., Chen, W., Hosseini, M., Behjati, F., Haas, S., Jamali, P., Zecha, A., Mohseni, M., and 33 others. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature 478: 57-63, 2011. [PubMed: 21937992] [Full Text: https://doi.org/10.1038/nature10423]
Nelson, J., Crowhurst, J., Carey, B., Greed, L. Incidence of the mucopolysaccharidoses in western Australia. Am. J. Med. Genet. 123A: 310-313, 2003. [PubMed: 14608657] [Full Text: https://doi.org/10.1002/ajmg.a.20314]
Neufeld, E. F. Personal Communication. Bethesda, Md. 1973.
O'Brien, J. S. Sanfilippo syndrome: profound deficiency of alpha-acetylglucosaminidase activity in organs and skin fibroblasts from type-B patients. Proc. Nat. Acad. Sci. 69: 1720-1722, 1972. [PubMed: 4261742] [Full Text: https://doi.org/10.1073/pnas.69.7.1720]
Pande, H., Chester, A., Lie, H., Thorsby, E., Stormorken, H. Concomitant occurrence of mucopolysaccharidosis IIIB and Glanzmann's thrombasthenia: further evidence of a hyperactive alpha-N-acetylglucosaminidase-producing allele. Clin. Genet. 41: 243-247, 1992. [PubMed: 1606713] [Full Text: https://doi.org/10.1111/j.1399-0004.1992.tb03674.x]
Pericak-Vance, M. A., Vance, J. M., Elston, R. C., Namboodiri, K. K., Fogle, T. A. Segregation and linkage analysis of alpha-N-acetyl-D-glucosaminidase (NAG) levels in a black family. Am. J. Med. Genet. 20: 295-306, 1985. [PubMed: 3976723] [Full Text: https://doi.org/10.1002/ajmg.1320200213]
Tanaka, A., Kimura, M., Lan, H. T. N., Takaura, N., Yamano, T. Molecular analysis of the alpha-N-acetylglucosaminidase gene in seven Japanese patients from six unrelated families with mucopolysaccharidosis IIIB (Sanfilippo type B), including two novel mutations. J. Hum. Genet. 47: 484-487, 2002. [PubMed: 12202988] [Full Text: https://doi.org/10.1007/s100380200070]
Tessitore, A., Villani, G. R. D., Di Domenico, C., Filocamo, M., Gatti, R., Di Natale, P. Molecular defects in the alpha-N-acetylglucosaminidase gene in Italian Sanfilippo type B patients. Hum. Genet. 107: 568-576, 2000. [PubMed: 11153910] [Full Text: https://doi.org/10.1007/s004390000429]
van Schrojenstein-de Valk, H. M. J., van de Kamp, J. J. P. Follow-up on seven adult patients with mild Sanfilippo B-disease. Am. J. Med. Genet. 28: 125-129, 1987. [PubMed: 3118713] [Full Text: https://doi.org/10.1002/ajmg.1320280118]
Vance, J. M., Conneally, P. M., Wappner, R. S., Yu, P. L., Brandt, I. K., Pericak-Vance, M. A. Carrier detection in Sanfilippo syndrome type B: report of six families. Clin. Genet. 20: 135-140, 1981. [PubMed: 6796309] [Full Text: https://doi.org/10.1111/j.1399-0004.1981.tb01818.x]
Vance, J. M., Pericak-Vance, M. A., Elston, R. C., Conneally, P. M., Namboodiri, K. K., Wappner, R. S., Yu, P. L. Evidence of genetic variation for alpha-N-acetyl-D-glucosaminidase in black and white populations: a new polymorphism. Am. J. Med. Genet. 7: 131-140, 1980. [PubMed: 6781343] [Full Text: https://doi.org/10.1002/ajmg.1320070207]
Vellodi, A., Young, E., New, M., Pot-Mees, C., Hugh-Jones, K. Bone marrow transplantation for Sanfilippo disease type B. J. Inherit. Metab. Dis. 15: 911-918, 1992. [PubMed: 1293388] [Full Text: https://doi.org/10.1007/BF01800232]
von Figura, K., Hasilik, A., Steckel, F., van de Kamp, J. Biosynthesis and maturation of alpha-N-acetylglucosaminidase in normal and Sanfilippo B-fibroblasts. Am. J. Hum. Genet. 36: 93-100, 1984. [PubMed: 6421152]
von Figura, K., Kresse, H. Quantitative aspects of pinocytosis and intracellular fate of N-acetyl-alpha-D-glucosaminidase in Sanfilippo B fibroblasts. J. Clin. Invest. 53: 85-90, 1974. [PubMed: 4271574] [Full Text: https://doi.org/10.1172/JCI107563]
von Figura, K., Logering, M., Mersmann, G., Kreese, H. Sanfilippo B disease: serum assays for detection of homozygous and heterozygous individuals in three families. J. Pediat. 83: 607-611, 1973. [PubMed: 4269738] [Full Text: https://doi.org/10.1016/s0022-3476(73)80222-7]
Wenger, S. L., McIntire, S. C., Bansal, V., Barranger, J. A., Higgins, J., Balistreri, W. F., Thompson, J. N., Deka, R. Glycogen storage disease type Ia and Sanfilippo syndrome type B in a patient with a balanced translocation. (Letter) Clin. Genet. 58: 409-410, 2000. [PubMed: 11140844] [Full Text: https://doi.org/10.1034/j.1399-0004.2000.580514.x]
Yogalingam, G., Weber, B., Meehan, J., Rogers, J., Hopwood, J. J. Mucopolysaccharidosis type IIIB: characterisation and expression of wild-type and mutant recombinant alpha-N-acetylglucosaminidase and relationship with Sanfilippo phenotype in an attenuated patient. Biochim. Biophys. Acta 1502: 415-425, 2000. [PubMed: 11068184] [Full Text: https://doi.org/10.1016/s0925-4439(00)00066-1]
Zhao, H. G., Li, H. H., Bach, G., Schmidtchen, A., Neufeld, E. F. The molecular basis of Sanfilippo syndrome type B. Proc. Nat. Acad. Sci. 93: 6101-6105, 1996. [PubMed: 8650226] [Full Text: https://doi.org/10.1073/pnas.93.12.6101]